Targeted reduction of the mutant α-synuclein transcripts should therefore be considered the ideal strategy for treating these hereditary forms of PD bearing mutations in α-synuclein due to sparing of the essential wild-type function. The gene discussed is SNCA; the disease is Parkinson disease.